LANCET ONCOL
| 中国学者近期发表的论文 | |
|---|---|
| 1. | Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Author: Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J, Qiu SJ, Shi YH, Yu B, Tang N, Chu W, Wang M, Wu J, Zhang Z, Yang S, Gu J, Wang H, Qin W. Journal: Lancet Oncol. 2012 Aug;13(8):817-26. doi: 10.1016/S1470-2045(12)70233-4. Epub 2012 Jun 26. |
| 2. | Author: Journal: |
| 3. | Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Author: Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, He QM, Jiang N, Chen L, Cho WC, Yun JP, Zeng J, Liu LZ, Li L, Guo Y, Wang HY, Ma J. Journal: Lancet Oncol. 2012 Jun;13(6):633-41. doi: 10.1016/S1470-2045(12)70102-X. Epub 2012 May 3. |
| 4. | Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Author: Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M; INFORM investigators. Collaborators (28)Zhang L, Ma SL, Han BH, Song XQ, Cheng Y, Huang C, Zhang L, Yang SJ, Liu XQ, Liu YP, Wang MZ, Lu S, Zhang SC, Lu KH, Zhou JY, Hou M, Cai L, Wu G, Zhao H, Fan M, Liu WC, Wang J, Liang J, Zhou CC, Pulmonary SH, Li Q, Wang CL, Wu SX. Journal: Lancet Oncol. 2012 May;13(5):466-75. doi: 10.1016/S1470-2045(12)70117-1. Epub 2012 Apr 17. |
| 5. | Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Author: Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J. Journal: Lancet Oncol. 2012 Feb;13(2):163-71. doi: 10.1016/S1470-2045(11)70320-5. Epub 2011 Dec 7. |
| 6. | LUX-Lung 7: is there enough data for a final conclusion? Author: Hu C, Zhang H, Zhang Y, Wu F, Ma JA. Journal: Lancet Oncol. 2016 Jul;17(7):e266-7. doi: 10.1016/S1470-2045(16)30117-6. No abstract available. |
| 7. | SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. Author: Abdel-Fatah TM, Agarwal D, Liu DX, Russell R, Rueda OM, Liu K, Xu B, Moseley PM, Green AR, Pockley AG, Rees RC, Caldas C, Ellis IO, Ball GR, Chan SY. Journal: Lancet Oncol. 2016 Jul;17(7):1004-18. doi: 10.1016/S1470-2045(16)00174-1. Epub 2016 Jun 14. |
| 8. | Immunotherapy for small-cell lung cancer. Author: Li Y, Wu YL. Journal: Lancet Oncol. 2016 Jul;17(7):846-7. doi: 10.1016/S1470-2045(16)30159-0. Epub 2016 Jun 4. No abstract available. |
| 9. | Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Author: Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, Havel L, Kondo H, Mitsudomi T, Zarogoulidis K, Gladkov OA, Udud K, Tada H, Hoffman H, Bugge A, Taylor P, Gonzalez EE, Liao ML, He J, Pujol JL, Louahed J, Debois M, Brichard V, Debruyne C, Therasse P, Altorki N. Journal: Lancet Oncol. 2016 Jun;17(6):822-35. doi: 10.1016/S1470-2045(16)00099-1. Epub 2016 Apr 27. |
| 10. | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Author: Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Journal: Lancet Oncol. 2016 May;17(5):577-89. doi: 10.1016/S1470-2045(16)30033-X. Epub 2016 Apr 12. |
| 同类著名期刊名称 | 影响因子 |
|---|---|
| CA-A CANCER JOURNAL FOR CLINICIANS | 101.780 |
| NATURE REVIEWS CANCER | 37.545 |
| CANCER CELL | 26.566 |
| JOURNAL OF CLINICAL ONCOLOGY | 18.372 |
| JNCI-Journal of the National Cancer Institute | 13.757 |
| Nature Reviews Clinical Oncology | 11.963 |
| CANCER AND METASTASIS REVIEWS | 10.573 |
| CANCER RESEARCH | 7.856 |
| CLINICAL CANCER RESEARCH | 7.742 |
| SEMINARS IN CANCER BIOLOGY | 6.475 |